Dual antiplatelet therapy: Difference between revisions
(New page: {{CMG}} {{SI}} {{EJ}} ==Superiority of Dual Antiplatelet Therapy Over Coumadin Plus Aspirin== Several studies during the early stent era demonstrated the superiority of the combination ...) |
|||
| Line 5: | Line 5: | ||
{{EJ}} | {{EJ}} | ||
==Superiority of Dual Antiplatelet Therapy Over Coumadin Plus Aspirin== | ==Superiority of Dual Antiplatelet Therapy (Thienopyridine Plus Aspirin) Over Coumadin Plus Aspirin in PCI Patients== | ||
Several studies during the early stent era demonstrated the superiority of the combination of [[ticlopidine]] plus [[aspirin]] over [[coumadin]] plus aspirin. has deployment <ref>Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-222.</ref><ref>Urban P, Macayo C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATIS). Circulation 1998;98:2126-2132.</ref><ref>Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.</ref><ref>Leon MG, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1667.</ref><ref>Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-1603.</ref>. | Several studies during the early stent era demonstrated the superiority of the combination of [[ticlopidine]] plus [[aspirin]] over [[coumadin]] plus aspirin. has deployment <ref>Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-222.</ref><ref>Urban P, Macayo C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATIS). Circulation 1998;98:2126-2132.</ref><ref>Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.</ref><ref>Leon MG, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1667.</ref><ref>Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-1603.</ref>. While progress was made over coumadin, Ticlopidine itself was associated with side effects and complications which included [[neutropenia]] in > 1%, [[thrombotic thrombocytopenia purpura]] in 0.2%, rash, [[nausea]]and [[diarrhea]]<ref>Steinhubl SR, Tan WA, Foody JM, et al., for the EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999;281:806-810.</ref>. Given the improved side effect profile and the results of the CLASSICS study, clopidogrel has replaced ticlopidine as the thienopyridine of choice <ref>Bertrand ME, Hans-Jürgen R, et al., for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation 2000;102:624-629.</ref><ref>Mueller C, Buttner JH, Petrerson J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590-593.</ref><ref>Taniuchi M, Kurz HI, Smith SC, et al. Ticlid or Plavix Post-Stents (TOPPS) (Abstr). Circulation 1999;100(Suppl I):I-379</ref>. | ||
==Data is Lacking Regarding the Safety and Efficacy of Thienopyridine Monotherapy Versus Thienopyridine Plus Aspirin Therapy in the Aspirin Intolerant Patient== | |||
One question that arises among patients who have [[aspirin hypersensitivity]] is the safety and efficacy of thienopyridine monotherapy in the mangement of the PCI patient including those who have been stented. There is one single center, small randomized trial purporting comparing the safety and efficacy of thienopyridine monotherapy to that of thienopyridine plus aspirin<ref>Machraoui A, Germing A, Lindstaedt M, et al. Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting. Follow-up results of a randomized study. J Invas Cardiol 2001;13:431-436.</ref>. 378 stents were placed in 243 patients who were randomly assigned to treatment with either 2 x 250 mg of ticlopidine (n=121) or the combination of 2 x 250 mg ticlopidine + 100 mg aspirin (122 patients) daily. '''''All patients received 500 mg of intravenous aspirin at the time of the procedure.''''' Two hundred and thirty-seven patients (97.5%) were free from death, cardiac events and vascular access-site complications through three months with no differences between treatment groups. Although 2 stent thromboses were observed in the combined treatment group, none were observed in the ticlopidine monotherapy group. There are several important limitations to this study. One is the fact that all patients recieved a high (500 mg) intravenous aspirin during the PCI which would have led to significant levels of platelet inhibition over the next week due to irreversible acetylation and inhibition of prostaglandin H-synthase/cyclooxygenase<ref>Awtry EH, Loscalzo J. Aspirin. Cardiovascular Drugs. Circulation 2000;101:1206-1218.</ref>. This is a period of high vulnerability to stent thrombosis and ischemic complications<ref>Wilson S, Rihal CS, Bell MR, et al. Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol 1999;83:1006-1011.</ref>. Thus, this was not truly a study of thienopyridine monotherapy. The study by Machraoui is also limited by its small sample size. Finally, the study administered [[ticlopidine]], which is not a pro-drug and may be associated with a lower rate of hyporesponsiveness than clopidogrel. | |||
==References== | ==References== | ||
Revision as of 19:33, 2 July 2010
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Superiority of Dual Antiplatelet Therapy (Thienopyridine Plus Aspirin) Over Coumadin Plus Aspirin in PCI Patients
Several studies during the early stent era demonstrated the superiority of the combination of ticlopidine plus aspirin over coumadin plus aspirin. has deployment [1][2][3][4][5]. While progress was made over coumadin, Ticlopidine itself was associated with side effects and complications which included neutropenia in > 1%, thrombotic thrombocytopenia purpura in 0.2%, rash, nauseaand diarrhea[6]. Given the improved side effect profile and the results of the CLASSICS study, clopidogrel has replaced ticlopidine as the thienopyridine of choice [7][8][9].
Data is Lacking Regarding the Safety and Efficacy of Thienopyridine Monotherapy Versus Thienopyridine Plus Aspirin Therapy in the Aspirin Intolerant Patient
One question that arises among patients who have aspirin hypersensitivity is the safety and efficacy of thienopyridine monotherapy in the mangement of the PCI patient including those who have been stented. There is one single center, small randomized trial purporting comparing the safety and efficacy of thienopyridine monotherapy to that of thienopyridine plus aspirin[10]. 378 stents were placed in 243 patients who were randomly assigned to treatment with either 2 x 250 mg of ticlopidine (n=121) or the combination of 2 x 250 mg ticlopidine + 100 mg aspirin (122 patients) daily. All patients received 500 mg of intravenous aspirin at the time of the procedure. Two hundred and thirty-seven patients (97.5%) were free from death, cardiac events and vascular access-site complications through three months with no differences between treatment groups. Although 2 stent thromboses were observed in the combined treatment group, none were observed in the ticlopidine monotherapy group. There are several important limitations to this study. One is the fact that all patients recieved a high (500 mg) intravenous aspirin during the PCI which would have led to significant levels of platelet inhibition over the next week due to irreversible acetylation and inhibition of prostaglandin H-synthase/cyclooxygenase[11]. This is a period of high vulnerability to stent thrombosis and ischemic complications[12]. Thus, this was not truly a study of thienopyridine monotherapy. The study by Machraoui is also limited by its small sample size. Finally, the study administered ticlopidine, which is not a pro-drug and may be associated with a lower rate of hyporesponsiveness than clopidogrel.
References
- ↑ Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-222.
- ↑ Urban P, Macayo C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATIS). Circulation 1998;98:2126-2132.
- ↑ Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
- ↑ Leon MG, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-1667.
- ↑ Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-1603.
- ↑ Steinhubl SR, Tan WA, Foody JM, et al., for the EPISTENT Investigators. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999;281:806-810.
- ↑ Bertrand ME, Hans-Jürgen R, et al., for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting. Circulation 2000;102:624-629.
- ↑ Mueller C, Buttner JH, Petrerson J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590-593.
- ↑ Taniuchi M, Kurz HI, Smith SC, et al. Ticlid or Plavix Post-Stents (TOPPS) (Abstr). Circulation 1999;100(Suppl I):I-379
- ↑ Machraoui A, Germing A, Lindstaedt M, et al. Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting. Follow-up results of a randomized study. J Invas Cardiol 2001;13:431-436.
- ↑ Awtry EH, Loscalzo J. Aspirin. Cardiovascular Drugs. Circulation 2000;101:1206-1218.
- ↑ Wilson S, Rihal CS, Bell MR, et al. Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. Am J Cardiol 1999;83:1006-1011.